Balanced Dysfunction in the Healthcare Ecosystem Harms Patients.

Robert M Califf,Robert M. Califf

DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.043935

IF: 37.8

2019-12-05

Circulation

Abstract:When elephants fight, it is the grass that suffers. —African proverb The foundational strategy for preventing cardiovascular disease (CVD) and recurrent cardiovascular events consists of lowering levels of low-density lipoprotein cholesterol (LDL-C), controlling blood pressure, and preventing and treating diabetes mellitus, combined with smoking avoidance and cessation, a healthy diet, and regular exercise. Despite decades of global progress in implementing risk factor reduction, progress has plateaued, and a recent uptick in risk has been observed in many areas characterized by lower income and lower levels of education. 1 In the United States, a significant increase in cardiometabolic disease resulting from the erosion of gains in modifying common risk factors has combined with opioid overdose and rising suicide rates to drive a downward trajectory in average life expectancy for 4 years in a row. 2 I approach this topic with significant conflicts of interest. As a former Commissioner of the US Food and Drug Administration, I have regulated LDL-C–lowering drugs. I have also conducted clinical trials, advised pharmaceutical companies, practiced cardiovascular medicine, and served as an institutional official for a large academic medical center and its health system, and I currently work for a company with an interest in the prevention and treatment of CVD. Therefore, my views and comments on the issue should be considered in light of these interactions, prior expressed beliefs, and financial conflicts. Although dietary and behavioral approaches to lowering LDL-C should be attempted, the results are modest and, for a majority of patients over longer intervals, only partly sustainable despite behavioral intervention. The use of statins, a class of drug that prevents the production of cholesterol by the liver, substantially reduces LDL-C and cardiovascular events, including death, stroke, myocardial infarction, and other sequelae of vascular disease. However, during the first decade that statins were broadly available, substantial cynicism directed toward the drugs fueled uncertainty that ultimately limited their use in clinical practice. Analyses show reduced use of statins and associated increases in cardiovascular events and death in countries when negative reports about statins appeared in popular media. 3 Statins eventually achieved blockbuster status after multiple blinded randomized trials conducted in large populations confirmed a substantial benefit in terms of lowering rates of cardiovascular events, particularly in people who had already had such an event. Unfortunately, however, despite the use of statins coupled with good-faith efforts at diet modification, many continue to be at risk of cardiovascular events because of elevated levels of LDL-C. The Need for Alternatives to Behavioral Interventions and Statins in CVD Even individuals with what were previously considered normal levels of LDL-C but also a high residual risk of recurrent CVD have been shown to benefit from further lipid lowering. The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) demonstrated that the cholesterol absorption inhibitor ezetimibe can provide additional, albeit modest, reduction of cardiovascular events when added to high-intensity statin therapy. 4 Although the use of ezetimibe in primary prevention has never been evaluated, its effect in secondary prevention is entirely consistent with predictions based on the effect of statins: a small reduction in LDL-C resulting in a small reduction in cardiovascular events. Now that multiple generic versions of ezetimibe are available, its price has dropped substantially and is now commensurate with its modest value in reducing events. The Advent of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Drugs Most recently, a scientific tour de force resulted in the development of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Over a short period, a human genetic polymorphism associated with lower low-density lipoprotein levels and lower cardiovascular event rates in epidemiological studies was translated into functional models at multiple preclinical levels, enabling target identification and the development of therapeutic molecules. The companies that won the race to develop PCSK9 inhibitors moved through development rapidly and were granted approval to market their drugs in limited populations on the basis of the demonstration of dramatic reductions in LDL-C levels without any accompanying serious toxicity. Before marketing approval, large clinical outcomes trials wer -Abstract Truncated-

cardiac & cardiovascular systems,peripheral vascular disease